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1. Introduction 
The earliest therapeutic application of 
liposomal antimicrobial therapy was for the 
treatment of leishmaniasis in experimental ani- 
mals [1,2], and published in 1978. In this case 
delivery of antimicrobial agent to infected Kup- 
ffer cells was accomplished using liposomes as 
carrier systems. Leishmaniu species are intracel- 
lular protozoa which are usually located in re- 
ticuloendothelial cells. 
In a variety of intracellular parasitic, bacterial 
and viral infections the effect of liposomal en- 
capsulation of antimicrobial agents on their ther- 
apeutic activity was further investigated. Based 
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on the data obtained in experimental infections 
clinical studies in patients were started. 
In the experimental models and clinical studies 
published to date ‘classical’ liposomes composed 
primarily of natural phospholipids and choles- 
terol were used. These liposomes, when adminis- 
tered intravenously, are unable to leave the 
general circulation and rapidly accumulate in 
cells of the mononuclear phagocyte system 
(MPS), particularly in liver and spleen. Accord- 
ingly, it is not surprising that most experimental 
data on the successful application of liposomes as 
carriers of antibiotics are derived from infections 
in MPS tissues caused by facultative or obligate 
intracellular pathogens. 
The applicability of classical liposomes for 
delivery of antibiotic to extracellular infections in 
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non-MPS tissues has been strongly limited by 
their short stay in blood due to the preferential 
uptake by the cells of the MPS. The use of 
liposomes as antibiotic carriers for treatment of 
infections outside the MPS would require a 
prolonged circulation half-life of hposomes. Re- 
cent progress in liposome design has yielded a 
new generation of liposomes characterized by 
long circulation half-lives and reduced hepato- 
splenic uptake. These liposome formulations, 
that show great promise for enhanced delivery of 
antibiotics in infectious diseases not restricted to 
MPS tissues, will not be discussed here. 
2. Intracellular infections 
Microorganisms that can survive and multiply 
intracellularly are protected from host defence 
mechanisms. Their intracellular location serves 
as a reservoir which is thought to be of impor- 
tance in recurrent infections. 
When invading pathogens have crossed one of 
the epithelial surfaces, they may spread through 
the body in various ways. The blood is the most 
effective vehicle of all for the spread of micro- 
organisms. Macrophages are present in all major 
compartments of the body, and those lining the 
sinusoids in the liver, spleen, bone marrow and 
adrenals are particularly involved in removing 
foreign particles and microorganisms from the 
blood. These macrophages constitute the MPS, 
and the liver macrophages (Kupffer cells) are 
quantitatively the most important part of the 
MPS. After being removed from the blood, the 
behaviour of the microorganism in the macro- 
phage becomes of great importance. Killing of 
the microorganism could mean termination of 
the infection, whereas microbial persistence and 
growth in the macrophage could lead to infection 
in the organ harbouring the macrophages, and 
hence to recurrent infection of the blood. Foci of 
infection in the liver, spleen and sometimes the 
bone marrow are characteristics of infections 
caused by intracellular pathogens. 
Intracellular microorganisms can survive and 
even multiply intracellularly in various cell types, 
most of them even in macrophages and other 
phagocytes [3-S]. Obligate intracellular micro- 
organisms such as Mycobacterium leprae, and 
non-bacterial pathogens such as Chlamydia spp. 
or Leishmania spp. are host cell-dependent, 
cannot live in the extracellular space, and are 
exclusively found in the intracellular environ- 
ment. In contrast, facultative intracellular micro- 
organisms reside intracellularly transiently. 
Mycobacterium tuberculosis, Brucella spp., Sal- 
monella spp., Legionella pneumophila, Listeria 
monocytogenes, and Neisseria gonorrhoeae are 
among facultative intracellular pathogens. These 
microorganisms are resistant to the intracellular 
killing mechanisms of these cells, and most of 
them actually multiply intracellulary. Normally 
phagocytosis of microorganisms is followed by 
fusion of the phagosome containing the bacteria 
with lysosomal granules present in the cell cyto- 
plasm. Phagosome-lysosome fusion results in 
oxygen-dependent and oxygen-independent bac- 
terial killing mechanisms in which the enzymes 
and cationic peptides present in the granules play 
an important role. 
Different pathogens use various ways of evad- 
ing intracellular killing to survive intracellularly: 
by escaping the phagosome followed by entry 
into the cytoplasm, or by inhibiting fusion of the 
lysosomes with the phagosomes, or by resisting 
the oxidative and non-oxidative killing mecha- 
nisms in phagolysosome. 
3. Antibiotic treatment of intracellular 
infections 
Eradication of intracellular infections is depen- 
dent on antibiotics, and is difficult due to the 
intracellular location of the microorganisms. In 
addition, the quiescent character of many in- 
tracellular pathogens prevents many antibiotics 
from expressing their activity. 
Insight in the intracellular activity of antibiot- 
ics is of great importance. For successful treat- 
ment the penetrating capacity of the antibiotic 
into the infected cell as well as the subcellular 
distribution of antibiotics within the cell are 
important determinants [5-71. 
The antibiotics enter cells via various mecha- 
nisms: passive transport via diffusion or active 
transport via transport proteins. Antibiotics dis- 
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play great variations in their ability to penetrate 
into the host cell. Some antibiotics show poor or 
slow intracellular penetration; others achieve 
roughly similar intracellular and extracellular 
concentrations. In contrast, there are antibiotics 
that actually accumulate within the cell. How- 
ever, the achievement of substantial intracellular 
antibiotic concentrations does not necessarily 
guarantee intracellular antimicrobial activity, 
even against susceptible infectious organisms. 
Sufficient antibiotic concentration in the intracel- 
lular location of the pathogen has to be achieved. 
The subcellular distribution of antibiotics is not 
uniform, showing important variations according 
to the antibiotic considered. The location of the 
intracellular pathogen is not uniform either. 
The subcellular distribution of antibiotics is 
reviewed by Tulkens [6]. Intracellularly the anti- 
biotic may be present in an endosome, or in 
lysosomes, or may be located in the cytoplasm. 
The antibiotic activity is diversely influenced by 
various factors such as the local pH, presence of 
proteins, enzymatic inactivation, ionic concen- 
trations and other factors. 
Aminoglycosides are too polar to pass across 
membranes, and are therefore only slowly taken 
up probably by endocytosis. As a result these 
agents are almost exclusively localized in lyso- 
somes, and as a consequence xposed to acid pH; 
they are not homogeneously distributed within 
cells. Only after long-term incubation relatively 
high concentrations are achieved in lysosomes. 
Penicillins and cephalosporins diffuse slowly 
through membranes of cells resulting in low 
intracellular concentrations. Even after long- 
term exposure of cells the intracellular concen- 
trations are lower than the extracellular con- 
centrations. These agents are found free in the 
cell cytosol. Lincosaminides can be found both in 
the cytosol and the lysosomes. Clindamycin ac- 
cumulates in phagocytes, whereas lincomycin is 
not accumulated by phagocytes. Macrolides also 
show both a cytosolic and a lysosomal localiza- 
tion. As with lincosaminides differences are 
observed among the various derivatives. Most 
agents, among which erythromycin, show a mark- 
ed intracellular accumulation. Fluoroquinolones 
also accumulate rapidly in cells, and are primari- 
ly found in the cytosol. Tetracyclines and 
chloramphenicol have been reported to accumu- 
late in cells to a moderate extent, Rifampicin 
also accumulates in cells, and shows a high 
efficacy against sensitive bacteria in many 
studies. However, the accumulation ratios are 
relatively low, in spite of the high liposolubility 
of the agent. Rifampicin is distributed in the 
cytosol. 
The intracellular antimicrobial activity of the 
antibiotic is also dependent of the microorga- 
nism’s specific intracellular environment. 
Pathogens frequently reside within phagosomes. 
When phagosome-lysosome fusion occurs, the 
pathogen-containing vacuole is flooded with 
acidic and toxic lysosomal products. However, 
some bacteria escape from the phagosome to the 
cytoplasm or inhibit phagosome-lysosome fusion 
(as described earlier in this review). 
It is clear that to predict intracellular activity 
of antibiotics is very complicated. In order to 
circumvent these difficulties investigators have 
proposed a more pragmatic approach. The anti- 
microbial activity of antibiotics can be evaluated 
by adding the compounds to pre-infected cells 
(phagocytes). After incubation the remaining 
intracellular microorganisms are counted. The 
studies available on the antimicrobial activity of 
a number of antibiotics against microorganisms 
ingested by mononuclear phagocytes are re- 
viewed [8,9], and show many apparently conflict- 
ing results. Various types of macrophages are 
used for these studies: animal macrophages 
which are usually collected from the peritoneal 
cavity of mice, rabbits or guinea pigs. The macro- 
phages can be resident or exudate (the latter 
being cells harvested after the administration of 
an inflammatory stimulus). Peritoneal macro- 
phages cannot be considered representative of all 
types of macrophage, as macrophages from vari- 
ous sites differ in a number of characteristics. It 
is difficult to obtain human tissue macrophages. 
Human monocytes isolated from the blood can 
also be used for such studies. The question is to 
what extent these mononuclear phagocytes are 
representative of human tissue macrophages in 
vivo. 
In addition to the variation in cell types used 
for these studies, the duration of incubation and 
the type of pathogen (including its subcellular 
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location) are all variables which must be careful- 
ly taken into account. Moreover there are meth- 
odological problems, especially when dealing 
with microorganisms that can grow both extracel- 
lularly and intracellularly. Caution must be exer- 
cised in drawing conclusions from the experimen- 
tal data concerning the treatment of intracellular 
infections. 
4. Liposomal encapsulation of antibiotic for 
treatment of intracellular infections 
Improvement of the activity of antibiotics 
against microorganisms located inside cells has 
been achieved by entrapment of the antibiotic 
within liposomes. Classical liposomes, intraven- 
ously injected, are rapidly removed by the 
phagocytic cells of the liver and spleen and are at 
least partly localized in lysosomes where they are 
slowly degraded. Advantage is taken of this 
behaviour to treat infections located within these 
cells. The actual amount of classical liposomes 
taken up by the liver and spleen is dependent on 
the dose of lipid administered. With small doses 
most liposomes are retained by the liver. With 
large doses the clearance capacity of the liver 
may be overwhelmed, and uptake of liposomes 
by the spleen and bone marrow increases. 
Studies were performed in vitro in which various 
types of phagocytic or non-phagocytic ells infec- 
ted with a variety of microorganisms were ex- 
posed to antimicrobial agents in the free versus 
liposome-entrapped form. In addition, in ex- 
perimental models of intracellular infection the 
effect of liposomal encapsulation of antimicro- 
bial agents on their therapeutic activity was 
investigated. In spite of the numerous in vitro 
and in vivo studies the clinical application of 
liposome-encapsulated antibiotics in the treat- 
ment of infections caused by intracellular 
pathogens in still limited. 
In a variety of animal models of intracellular 
parasitic, bacterial and viral infections the effect 
of liposomal encapsulation of antimicrobial 
agents on their therapeutic activity was investi- 
gated. In general in all these studies an improved 
therapeutic effect and/or reduced toxicity re- 
sulting from encapsulation of the antibiotics in 
liposomes have been demonstrated. Most anti- 
biotics are relatively ineffective for intracellular 
infections due to poor penetration into the cells 
or decreased activity intracellularly. Administra- 
tion of antibiotic encapsulated in classical lipo- 
somes results in relatively high and prolonged 
concentrations of antibiotic in MPS tissues. 
The rationale of this approach was based on 
the hypothesis that the liposomes are taken up 
by the cells containing the intracellular 
pathogens, and hence increase the ability of the 
antibiotic to reach its target, and to act in the 
corresponding environment. Surprisingly, only 
very few studies deal with the intracellular loca- 
tion of the liposomes and infectious organisms. 
4.1. Parasitic infections 
The first studies were published in 1978, and 
applied to intracellular parasitic infections 
caused by Leishmania spp. [1,2,10]. Diseases 
caused by the intracellular parasite Leishmania, a 
haemoflagellate protozoan, is a very important 
disease with a high prevalence in tropical and 
subtropical areas throughout the world. The 
parasite, which resides exclusively in macro- 
phages in the MPS, has three different clinical 
manifestations: visceral (kala azar), mucocuta- 
neous, and cutaneous leishmaniasis. In humans, 
the untreated visceral disease which affects liver, 
spleen and bone marrow, is the most severe and 
usually fatal, the other forms are severe (or fatal) 
and recurrent despite treatment with antimonial 
compounds. The antimonials are limited in effec- 
tiveness because of severe systemic toxicities, 
particularly to the heart, kidney and liver. 
Macrophages are the preferred habitat of Leish- 
mania spp. which multiply in the phagolyso- 
some where they are resistant o digestion. Leish- 
mania donovani amastigotes are able to survive 
and metabolize in the acidic environment (pH 
4-5) found in the phagolysosomes, and in addi- 
tion are innately resistant to the lysosomal en- 
zymes. Leishmania major survives by preventing 
the triggering of the respiratory burst. 
By Alving et al. [l,lO] leishmaniasis was in- 
duced in hamsters by intracardial injection of 
Leishmaniu donovani. This resulted in a fatal 
infection in which the organism settles in the 
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cells of the MPS in the liver and spleen. Animals 
were treated intracardially with antimonial 
agents in the free or liposome-encapsulated 
form. Parameters for efficacy were effects on 
death rates or the total numbers of parasites per 
liver in surviving animals determined from im- 
pression smears. The studies reveal an increase 
in therapeutic efficacy of antimonial compound 
resulting from administration in the liposome- 
encapsulated form. The liposomal agent was at 
least 350 times as effective as the free agent in 
suppressing experimental leishmaniasis. Lipo- 
somes of various lipid compositions were used. 
The therapeutic efficacy was influenced by the 
lipid composition and the charge of the lipo- 
somes. The investigators found by empirical 
testing [l] that the lipid combinations that gave 
optimum therapeutic efficacy in leishmaniasis in 
hamsters are those that contain cholesterol and 
synthetic highly saturated phospholipids. Lipo- 
somes that are neutral or negatively charged are 
often more effective than positively charged 
ones. 
The rationale of this approach was based on 
the hypothesis that the liposomes are rapidly 
taken up by the same type of cells in which 
Leishmania organisms reside, i.e., the phagocytic 
cells of the MPS, predominantly the Kupffer cells 
of the liver. Electron microscopic evidence was 
presented that supports this hypothesis. Electron 
micrographs of liver and spleen showed intracel- 
lular parasites adjacent to liposomes. The mul- 
tilamellar structures of the liposomes were often 
not well preserved, but in some cases individual 
lamellae were sharply defined. 
The therapeutic studies in the model of leish- 
maniasis in hamsters were extended to other 
classes of antimonial compounds, &amino- 
quinolines, administered by various routes [ll]. 
Liposomes containing these agents were effective 
when given intracardially, intraperitoneally or 
intramuscularly, but not when given subcuta- 
neously or orally. One of the most potent agents 
was up to 1800 times more effective than the 
agent alone. Empty liposomes lacked therapeutic 
efficacy. 
Some years later similar observations have 
been made in dogs. Domestic dogs and wild 
canine species are the reservoirs for visceral 
leishmaniasis in the Americas, in the Middle 
East, and the Mediterranean basin [12]. In dogs 
intravenous Leishmania donovani infection re- 
sulted in visceral leishmaniasis of a focal charac- 
ter. Effective parasite suppression in the spleen 
obtained for intravenous treatment with the 
liposome-encapsulated agent was 700 times more 
efficacious than the unencapsulated rug. 
In the model of leishmaniasis in hamsters the 
influence of parasite virulence on the effective- 
ness of liposomes in the treatment of visceral 
leishmaniasis was investigated [13]. The distinc- 
tive types of infection varied with respect to 
death rate and hepatic parasite counts. In every 
case, regardless of the type of infection the 
liposome-encapsulated agent was far superior to 
the non-encapsulated agent. However, even 
when the liposomal agent was employed, in the 
most virulent infections a fraction of animals 
appeared to be refractory to treatment. 
At the same time of the first studies of Alving 
et al. in 1978 New et al. [2], from another 
laboratory, reported the successful use of lipo- 
somes as carriers of antimonials for intravenous 
treatment of experimental visceral leishmaniasis 
caused by Leishmania donovani in mice. 
Two years later these investigators published 
studies performed in a model of cutaneous leish- 
maniasis caused by Leishmania major injected 
subcutaneously in mice [14]. In this infection the 
parasite is located in macrophages in peripheral 
tissues rather than in the liver. Free or liposome- 
encapsulated antimonial agent was administered 
by different routes (intralesion or intravenously). 
The efficacy of the antileishmanial agent was 
enhanced by entrapping it inside liposomes; after 
the cutaneous lesion had begun to develop the 
intravenous route of administration of liposomal 
agent was the most effective. 
The studies in experimental eishmaniasis de- 
scribed clearly show that liposomes may be 
useful as carriers of the therapeutic agents to 
treat infectious diseases involving the mononu- 
clear phagocyte system. In case of extremely 
toxic antimonial agents encapsulation of the 
agent and reduction of the dose required for 
effective therapy should minimize systemic toxic- 
ity. Less than 0.15% of an ordinary therapeutic 
dose can be used for equivalent therapy. 
The investigators have clearly shown in elec- 
tron microscopic studies in infected hamsters that 
antileishmanial agents inside liposomes have 
been brought into close contact with amastigotes 
in liver Kupffer cells [15]. The parasites, enclosed 
in so-called parasitophorous vacuoles, are able to 
survive after fusion with the lysosomes. Several 
hours after injection of liposomes, large numbers 
of vesicles are found in macrophages either in 
phagosomes or in lysosomes. The lysosomes 
containing liposomes commonly come into close 
apposition to leishmanial parasites. Instances of 
apparent fusion of the lysosomal membranes 
with parasitophorous vacuolar membranes are 
often observed. As a result the drug-laden lipo- 
somes are actually enclosed within the 
parasitophorous vacuole. Dramatic disintegration 
of Leishmania parasites in hamster Kupffer cells 
after treatment of the hamster with liposomal 
antimonial drug was shown, with remnants of 
liposomes observed. The high efficiency and 
precision of this process, involving liposomes as 
drug carriers and lysosomes as liposome carriers, 
probably accounts for the remarkable efficacy of 
liposome-encapsulated drugs in chemotherapy of 
leishmaniasis. 
In further studies investigations in experimen- 
tal leishmaniasis covered other compounds, such 
as amphotericin B, which exhibit antifungal ac- 
tivity. Antifungal agents were used based on 
possible biochemical similarities between fungi 
and protozoa. 
Mice with intravenously induced leishmaniasis 
were treated intravenously with various antifung- 
al agents [16]. All the agents tested displayed 
enhanced therapeutic activity when administered 
in the liposomal form. In the case of am- 
photericin B, liposomes composed of hydro- 
genated lecithins, or containing cholesterol or 
ergosterol in the membrane, were least toxic to 
the host and had the highest therapeutic capa- 
bility. Another study of visceral leishmaniasis in 
mice confirmed the observation that am- 
photericin B in the liposomal form is significantly 
more active than the free form [17]. 
Other investigators reported the treatment of 
models of cutaneous leishmaniasis caused by 
footpad inoculation with Leishmaniu tropica in 
two strains of mice [18]. 
In mice which develop only local infection 
intravenous liposomal amphotericin B did not 
result in a decreased number of tissue parasites. 
In the other mouse strain the foodpad infection 
resulted in dissemination of the organism and 
eventually death of mice; in this model there was 
a slight effect of liposomal amphotericin B equal 
to non-encapsulated amphotericin B. 
Also hamsters infected intracardially and 
squirrel monkeys infected intravenously with 
Leishmania donovani, resulting in visceral leish- 
maniasis, were treated with liposomal am- 
photericin B by the same route of administration 
as the Leishmania inoculation 1191. The am- 
photericin B liposomes consisted of dimyristoyl 
phosphatidylglycerol-dimyristoylphosphatidyl- 
choline (molar ratio, 3:7), the same liposomes as 
used by Lopez-Berestein et al. in human trials. 
Compared to non-encapsulated antimonial 
agents liposomal amphotericin B was far superior 
in both animal models. 
Industrially prepared Amphocil@ (am- 
photericin B Colloidal Dispersion) was also ap- 
plied by intracardial injection in hamsters with 
visceral leishmaniasis caused by intracardiac 
inoculation 
Amphocil@ 
of Leishmania donovani [20]. 
was 15 times (lightly infected ani- 
mals) or 4 times (heavily infected animals) as 
active as non-encapsulated amphotericin B. 
The antileishmanial activity of industrially pre- 
pared AmBisome@ was investigated in vitro as 
well as in animals [21]. Mouse peritoneal macro- 
phages infected with Leishmania donovani were 
exposed to antifungal agent. Both AmBisome@ 
and non-encapsulated amphotericin B effectively 
killed the intracellular amastigotes at equivalent 
concentrations. In mice intravenously infected 
with Leishmania donovani AmBisome@ was 
more effective compared to non-encapsulated 
amphotericin B. 
Recently it was reported that neoglycoprotein 
conjugation of liposomes increased their potency 
as macrophage drug delivery system in Leish- 
mania donovani infection [22]. In vitro in infec- 
ted murine peritoneal macrophages hamycin 
entrapped in conjugated liposomes eliminated 
intracellular amastigotes 1.5 times and 10 times 
more efficiently than did the agent when en- 
trapped in non-conjugated liposomes and in the 
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free form, respectively. In mice with visceral 
leishmaniasis hamycin in conjugated liposomes 
could completely eliminate splenic parasites, 
whereas when administered in non-conjugated 
liposomes it was only partly effective. 
The first clinical application of liposome-en- 
capsulated amphotericin B in leishmaniasis was 
reported in 1991 [23]. Successful treatment of a 
patient with Mediterranean multiply drug-resis- 
tant visceral leishmaniasis with AmBisome@ was 
achieved. When reviewed 2 months after treat- 
ment the patient was symptom-free and all 
laboratory tests were normal. 
There is a growing number of recent case 
reports demonstrating the efficacy of Am- 
Bisome@ in the treatment of drug-resistant 
visceral leishmaniasis [24]. In addition, Am- 
Bisome@ appeared to be effective in oral 
leishmanial esions [25] as well as antimony-resis- 
tant cutaneous leishmaniasis [26]. In endemic 
areas, visceral leishmaniasis is considered a HIV- 
associated opportunistic infection. AmBisome@ 
was also used for treatment of visceral leish- 
maniasis in AIDS patients unresponsive to 
antimonial compounds, and appeared to be ef- 
fective for treatment and prophylaxis [27-291. 
In spite of these observations on successful 
treatment it is important to be aware that relapse 
may occur. In two reports AIDS patients with 
visceral leishmaniasis are described who re- 
sponded to treatment with AmBisome@; how- 
ever infection recurred despite the administra- 
tion of maintenance therapy before the second 
relapse [30,31]. The authors presume that pa- 
tients coinfected with HIV and Leishmania have 
a large parasite burden; in such cases, amasti- 
gotes infect cells other than macrophages (e.g., 
epithelial cells and neutrophils), which might be 
an explanation for treatment failure. 
Summarizing, the experimental and clinical 
studies suggest that the use of AmBisome@ in 
the treatment of visceral leishmaniasis warrants 
further investigation. In immunocompromised 
patients comparative studies of induction and 
maintenance therapy are urgently needed. Par- 
ticularly in these patients visceral leishmaniasis 
has emerged as an important opportunistic in- 
fection, and is more prevalent; treatment is 
particularly problematic [32]. 
4.2. Viral infections 
The natural targeting of liposomes to cells of 
the MPS was also exploited to investigate 
whether selective delivery of antiviral agents 
could be beneficial for the treatment of viral 
diseases. Regarding viral infections these are 
always intracellular infections, in which many 
types of cells are involved. Virus replication in 
macrophages can be an integral factor in the 
pathogenesis of certain systemic virus infections. 
Macrophages, particularly the Kupffer cells, are 
extremely important as a barrier to prevent 
access of virus to other cell types. Incapacity of 
Kupffer cells in this respect, for example in the 
case of Rift Valley fever virus, enables the virus 
to pass straight to the endothelial cells and to 
infect the hepatic cells. It should be possible to 
direct antiviral agents to viruses replicating with- 
in macrophages. Besides, liposomes might also 
be targeted to other cell types by incorporating 
the appropriate antibodies into them. In that 
respect they should be ideal carriers of drugs to 
intracellular organisms such as viruses. 
Regarding viruses replicating inside macro- 
phages, experimental studies were performed 
with Rift Valley fever virus, which replication 
initially occurs inside the Kupffer cells, and later 
in macrophages of other visceral organs. Ad- 
ministration of liposome-encapsulated ribavirin 
to mice led to ribavirin concentrations in the 
liver, the primary site of Rift Valley fever virus 
proliferation, that were fivefold greater than 
those attained with the same doses of free 
ribavirin [33]. Liposomal ribavirin protected mice 
against a rapidly lethal challenge with Rift Valley 
fever virus, whereas similar doses of free drug or 
empty liposomes had no detectable benefit. 
Also in vitro studies were performed in cul- 
tured human monocyte-macrophages infected 
with the human immunodeficiency virus type-l 
(HIV-l). Cells of the monocyte-macrophage 
lineage are important hosts for the HIV-l, and 
play a key role in the dissemination of the virus 
and pathogenesis of AIDS, providing long-term 
reservoirs for the virus. The infected cells were 
exposed to various antiviral agents in the free or 
liposome-encapsulated form [34]. The liposomal 
agent and the free agent were equally potent. 
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The observations on cellular uptake suggest hat macrophages and macrophages infected with C. 
the antiviral drug was taken up by the cells inside albicans. Uptake and degradation of Am- 
the vesicles, probably by endocytosis. It was also Bisome@ in uninfected macrophages had no 
shown that the tissue distribution and plasma effects on subsequent C. albicans infection. Low 
pharmacokinetics of antiviral agent were modi- intracellular antifungal activity was found for 
fied when administered in the liposome-encapsu- AmBisome@ compared to free amphotericin B, 
lated form [35]. Further studies are warranted to which is probably the result of slow intracellular 
explore the use of liposomes in vivo in the degradation of AmBisome@ which is a solid 
chemotherapy of infections with HIV liposome type. 
4.3. Fungal infections 
Regarding fungal infections most studies are 
performed with the antifungal agent am- 
photericin B encapsulated in liposomes or bound 
to other lipid carriers with the main purpose of 
reduction of toxicity of this agent. Extensive 
animal studies have been performed with various 
preparations of liposomal or lipid-complexed 
amphotericin B [36-511. Various animal models 
of fungal infections were used. Fungal pathogens 
mostly used were Candida spp., Cryptococcus 
neoformans, Histoplasma capsulatum, Aspergil- 
lus spp., Coccidioides immitis and Blastomyces 
dermatitidis. Studies were performed in immuno- 
competent as well as immunodeficient animals. 
Various parameters for efficacy were used, such 
as animal survival rate, quantitative fungal cul- 
tures of infected organs as well as histological 
examination. 
From clinical practice it is known that dissemi- 
nated fungal infections require antifungal 
therapy; however, relapse after therapy is a 
common occurrence. Whereas it is known that 
certain intracellular fungal pathogens such as 
Cryptococcus neoformans and Histoplasma cap- 
sulatum particularly reside in the cells of the 
MPS, it is generally believed that relapse of 
infection after treatment of severe fungal in- 
fection may be caused by intracellularly surviving 
fungal pathogens. Fungi can be considered as 
facultative intracellular pathogens, as they are 
able to survive inside unactivated macrophages, 
and to grow out of these cells. Their intracellular 
location is thought to be of importance in re- 
current infections. In our laboratory it was ob- 
served (data not yet published) that liposomal 
amphotericin B (AmBisome@) is avidly taken up 
by macrophages in vitro, both by uninfected 
The experimental studies on therapeutic effica- 
cy clearly show that the antifungal activity of 
amphotericin B, dependent on the liposome or 
the lipid complex, is lower or equal compared to 
the non-encapsulated agent. However, in severe 
infections non-encapsulated amphotericin B 
could not be given at therapeutic levels because 
of toxicity; in the liposomal or lipid-complexed 
form amphotericin B, with its reduced toxicity, 
could be administered at drug levels capable of 
giving a therapeutic response. In other words, 
due to the decrease of toxicity these am- 
photericin B formulations display a marked in- 
creased therapeutic index. With respect to the 
industrially produced preparations AmBisome@, 
ABLC (amphotericin B Lipid Complex) and 
Amphocil@ (amphotericin B Colloidal Disper- 
sion) it is evident that these have quite different 
structural and pharmacokinetic characteristics 
[52]. These pharmacokinetics depend to a large 
extent on the composition and particle size of the 
liposomes or the lipid complexes. Lipid struc- 
tures such a ABLC and Amphocil@ are rapidly 
taken up by the MPS; as a result relatively high 
amphotericin B concentrations are obtained in 
the liver and spleen without signs of major 
amphotericin B toxicity in these organs. 
The promising results of the animal studies 
along with technical advances in liposomal prep- 
aration techniques have led to clinical applica- 
tion. Extensive clinical studies with various lipid 
formulations of amphotericin B have been in 
progress for several years [53]. The efficacy of 
liposomal amphotericin B in patients with hepa- 
tosplenic candidiasis, a very protracted and dif- 
ficult to treat infection, was good, and in patients 
with other infections encouraging. Most pub- 
lished clinical data on efficacy are available for 
AmBisome@ showing encouraging results in a 
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variety of fungal infections in immunocompro- 
mised patients [54-581. 
4.4. Bacterial infections 
With respect to intracellular bacterial infec- 
tions in MPS tissues in a number of animal 
infection models antibiotics were applied in the 
free or liposome-encapsulated form in most cases 
administered intravenously. Representative 
agents of various classes of antibiotics (amino- 
glycosides, penicillins, cephalosporins and 
quinolones) were used. 
Most studies with antimicrobials encapsulated 
in liposomes are performed in experimental 
infections caused by organisms of the genus 
mycobacteria [59]. Mycobacteria are intracellular 
organisms that invade and multiply particularly 
within phagocytic cells. Infections caused by 
Mycobacteriurn tuberculosis (tuberculosis) or 
Mycobacterium leprae (leprosy), or Mycobac- 
terium avium disseminated infections in AIDS 
patients are extremely common around the 
world. Treatment of mycobacterium infections is 
complicated, as sufficient concentrations of anti- 
microbials are needed within the intracellular 
compartment where the mycobacteria are lo- 
cated. In addition, resistance to antibiotics 
among mycobacteria is growing. Mycobacterium 
tuberculosis infects primarily pulmonary macro- 
phages, while Mycobacterium avium complex 
infects particularly reticuloendothelial macro- 
phages. 
The facultative intracellular bacterium 
Mycobacterium tuberculosis secretes molecules 
that prevent phagosome-lysosome fusion. The 
phagocytic vacuoles remain free from lysosomal 
enzymes, bacteria can survive and grow. The 
obligate intracellular bacterium Mycobacterium 
leprae is able to escape from the phagosome into 
the cytoplasm, where it is protected from 
lysosomal enzymes. Even when phagosome-lyso- 
some fusion occurs Mycobacterium spp. are resis- 
tant to lysosomal enzymes present in the 
phagolysosome due to their waxy cell wall that is 
very hydrophobic. 
In mice intravenous inoculation with Mycobac- 
terium tuberculosis resulted in infection of the 
spleen and lungs [60]. Intravenous injection of 
liposome-entrapped streptomycin led to a signifi- 
cant decrease in the spleen mycobacterium num- 
ber, but not in the lungs, as compared to free 
streptomycin. Comparative pharmacokinetic 
studies reveal that streptomycin concentrations 
in spleen and liver were higher when adminis- 
tered in the liposomal form, whereas strep- 
tomycin concentrations in lungs and kidneys 
were independent from the drug form (liposomal 
or free) of streptomycin [61]. 
In another study rifampicin and isoniazid en- 
trapped in liposomes were used for the treatment 
of murine tuberculosis [62]. The administration 
of liposome-entrapped rugs resulted in a signifi- 
cant reduction in the severity of the disease 
compared to the non-encapsulated rugs in terms 
of mycobacterium numbers in the spleen, as well 
as inflammation in the lungs determined by 
histology. It remains unanswered whether in- 
creased intracellular concentrations of drugs 
were achieved after administration in the 
liposomal form; it is known that rifampicin and 
isoniazid both penetrate cells well. 
Recently it was shown in a model of Mycobac- 
terium tuberculosis infection in mice that the 
antitubercular activity of rifampicin was con- 
siderably increased when it was encapsulated in 
liposomes. A further increase in the activity was 
observed when the macrophage activator tetra- 
peptide tuftsin was grafted on the surface of the 
drug-loaded liposomes [63]. It was clearly dem- 
onstrated that liposome targeting to macro- 
phages could considerably increase the an- 
titubercular activity of the agent. 
A number of experimental models of 
Mycobacterium avium complex infection are 
described and used for treatment studies [64-721. 
Particularly the beige mouse model of the dis- 
ease was used. In most studies mice were in- 
travenously infected. In beige mice this results in 
a chronic disseminated infection over a period of 
various weeks in which liver, spleen, lungs, kid- 
neys and lymph nodes are involved. A variety of 
antimycobacterial agents among which the 
aminoglycosides amikacin, gentamicin, strep- 
tomycin and kanamycin, rifampicin and cap- 
reomycin were administered intravenously. The 
studies clearly demonstrate that liposome-based 
delivery of the therapeutic agent enhances its 
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antimycobacterial effect. In most studies it is 
observed that the superior therapeutic effect of 
liposome-encapsulated agent is only seen in the 
spleen, and not in the lungs [60,61,64,66,68,71]. 
However, in some studies the increased thera- 
peutic effect of liposomal agent over non-en- 
capsulated agent was also observed in the lungs 
[65,64,70,72]. The discrepancies between these 
studies may be explained by differences in the 
lipid composition, and the total lipid doses used 
in the studies. Particularly the lipid dose is 
important, as with larger doses the ability of the 
liver to take up the liposomes from the circula- 
tion may be overwhelmed, and increasing 
amounts of liposomes are taken up by the spleen 
and bone marrow. 
Pharmacokinetic studies reveal that concen- 
trations of the antimycobacterial agents following 
administration in the liposome-encapsulated 
form are increased. In addition, data from in 
vitro studies suggest that intracellular delivery 
plays a role in the treatment of infections by 
Mycobacterium spp. The actual intracellular lo- 
cation of Mycobacterium avium complex is un- 
known. However, it has been shown that in vitro 
liposomes enhance the activity of antibiotics 
against Mycobacterium avium complex in 
phagocytic cells. In most cases monocytes or 
macrophages obtained from experimental ani- 
mals in culture were used [65,73-75,701; human 
monocytes/macrophages were also used [76-791. 
The cells were infected with Mycobacterium 
avium complex and exposed to antibiotics among 
which the aminoglycosides amikacin, strep- 
tomycin and kanamycin, ciprofloxacin, clo- 
fazimin, clarithromycin, ofloxacin, azithro- 
mycin, rifabutin and rifampicin in the lipo- 
some-encapsulated or free form. In general the 
studies show that Mycobacterium avium complex 
was effectively killed when the infected cells 
were exposed to the liposomal agent, whereas 
the same concentration of the non-encapsulated 
agent alone or in combination with placebo 
liposomes did not show an antimicrobial effect. 
Even for clarithromycin and ofloxacin, antimicro- 
bials that achieve high concentrations within 
macrophages, liposomal encapsulation signifi- 
cantly enhanced the activities [78]. It was ob- 
served that exposure of the infected cells to 
liposomal antibiotic at 4°C did not result in an 
intracellular antimicrobial effect, suggesting that 
liposomes need to be endocytosed to deliver 
their antibiotic intracellularly. 
Electron microscopy of Mycobacterium avium 
complex-infected macrophages revealed that the 
bacteria were localized in phagosomes [77]. 
Some bacteria in infected macrophages exposed 
to either free or liposome-encapsulated cipro- 
floxacin showed signs of degradation. It was not 
possible to discern differences between mycobac- 
teria inside macrophages treated with free cipro- 
floxacin and those inside macrophages treated 
with liposomal ciprofloxacin. Treatment of 
macrophages with placebo liposomes did not 
appear to cause bacterial degradation. 
The in vitro activities of free and liposomal 
antimycobacterial agents against extracellular 
Mycobacterium avium complex and Mycobac- 
terium tuberculosis were compared [80]. The 
results show that the antimycobacterial activities 
of certain drugs were maintained after the drugs 
were incorporated into liposomes. 
The efficacy of liposomal gentamicin for the 
treatment of Mycobacterium avium complex bac- 
teremia in AIDS patients was investigated [al]. 
Following intravenous administration of liposom- 
al gentamicin twice weekly for 4 weeks mycobac- 
terium numbers in blood fell substantially. 
In animal models of infection caused by 
facultative intracellular bacteria such as Sal- 
monella spp. [82-871, Brucella spp. [88, 891 and 
Listeria monocytogenes [90,86] comparative 
studies were performed on the therapeutic effica- 
cy of antibiotics in the liposome-encapsulated or 
non-encapsulated form. Mice or guinea pigs were 
infected intravenously; the intracellular bacteria 
concentrated primarily in the liver and spleen. 
Salmonella spp. and Brucella spp. owe their 
intracellular survival to their glycolipid capsule 
which is resistant to the action of lysosomal 
components following phagolysosome fusion (the 
non-oxidative killing mechanisms). Other bac- 
terial species among which Listeria monocyto- 
genes, Staphylococcus aureus and Escherichia 
coli stimulate a normal respiratory burst, but are 
resistant to the effects of the toxic oxygen radi- 
cals by production of catalase or superoxide 
dismutase, enzymes that destroy hydrogen perox- 
ide or superoxide. 
In the treatment of these intracellular infec- 
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tions in MPS tissues superior efficacy of anti- 
biotics when administered intravenously in the 
liposome-encapsulated form was observed. The 
parameter for efficacy was survival of animals or 
bacterial recovery from infected organs. The 
antibiotics that were applied were the amino- 
glycosides streptomycin, kanamycin and gen- 
tamicin, ciprofloxacin, cephalotin and ampicillin. 
Tissue distribution studies reveal substantially 
increased and more prolonged antibiotic con- 
centrations particularly in the liver and spleen, 
following administration in the liposomal form. 
Supplementary to these efficacy data obtained 
in models of bacterial infection, in vitro data on 
the role of liposomes in targeting of antibiotic to 
bacterial infected phagocytic cells also show the 
superiority of liposome-encapsulated antibiotics. 
Phagocytic cells were murine or guinea pig 
macrophages, canine monocytes, or bovine 
monocytes/macrophages. Monocytes or macro- 
phages infected with Salmonella spp. [91], 
Brucella spp. [88,89,92], Listeria monocytogenes 
[93,94], Staphylococcus aureus [95-971 or Es- 
cherichia coli [98] were exposed to the amino- 
glycosides streptomycin, amikacin, gentamicin, 
tobramycin and kanamycin, ampicillin, cephalo- 
thin and chloramphenicol in the free or 
liposome-encapsulated form. 
Studies were also performed with human 
monocytes/macrophages infected with Legionel- 
la pneumophilu [99]. The intracellular bacteria 
were effectively killed by liposomal antibiotics, at 
concentrations that in the free form did not show 
an antimicrobial effect. The studies performed 
with Listeria monocytogenes demonstrated that 
by varying the lipid composition of the liposomes 
the intracellular degradation of the liposomes 
could be influenced and thereby the rate at which 
liposome-encapsulated agents are released and 
become available to exert their therapeutic ac- 
tion [93]. 
5. Concluding remarks 
In view of their high affinity for the cells of the 
MPS, classical iposomes may serve as carriers of 
an appropriate antibiotic to intracellular sites of 
infection, particularly the liver and spleen. This is 
clearly demonstrated in a number of animal 
models of infection caused by facultative or 
obligate intracellular pathogens. After intraven- 
ous inoculation the microorganisms were rapidly 
cleared from the circulation and concentrated 
primarily in the liver and spleen. Often logarith- 
mic growth of microorganisms in these organs 
was shown to occur. 
Most studies have shown a significant improve- 
ment of liposome-encapsulated antimicrobials 
over free agent in the survival time of infected 
animals or a significant reduction in the number 
of microorganisms in infected organs. These 
observations are in line with the results obtained 
from in vitro studies in which infected phagocytic 
cells were exposed to liposome-encapsulated 
versus non-encapsulated antibiotic. The data 
suggest that administration of antibiotic in the 
liposome-encapsulated form may compensate for 
the poor penetration and/or retention of anti- 
biotic within the cell. However, for antimicro- 
bials that can achieve high concentrations within 
macrophages, liposomal encapsulation also re- 
sulted in significantly increased activities of the 
agents. 
The concentration of antibiotics at the site of 
infection using liposomes allows treatment with a 
lower dosage. This is an important observation 
also with respect to potentially toxic antibiotics 
such as the aminoglycosides which despite their 
toxicity still play an important antimicrobial role; 
the encapsulation into liposomes will change the 
pharmacokinetics of these agents resulting in 
reduction of nephrotoxicity [lOO]. 
To what extent intracellular concentration of 
antibiotic is also achieved using liposomes for 
treatment is difficult to investigate. Supporting 
evidence for this has only been obtained from 
electron microscopic studies in experimental leish- 
maniasis. In addition, numerous in vitro studies 
using infected phagocytic cells suggest that in- 
tracellular delivery of antibiotic by means of 
liposomes plays a role in the successful treatment 
of intracellular infections. Only very few studies 
deal with the intracellular location of the lipo- 
somes and the infectious organisms. Theoret- 
ically, the requirements for effective treatment of 
intracellular infections with liposome-encapsu- 
lated antibiotics are that next to intrinsic activity 
of antibiotic against the pathogen, the antibiotic 
must be at least considerably effective at the 
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relatively low pH range of the phagolysosomal 
environment as well as relatively resistant to 
degradation in this environment. 
Although liposome-encapsulated antibiotics 
are shown to be effective, in most studies the 
intracellular infection was not completely elimi- 
nated. Intracellular survival and multiplication of 
facultative or obligate intracellular microorga- 
nisms play a significant role in the pathogenesis 
of the diseases these organisms cause. Still 
liposomal encapsulation of antibiotic provides a 
therapeutic benefit by reducing the infectious 
load at least in the liver and spleen. 
Recent experience from clinical application of 
liposomal amphotericin B for leishmaniasis in 
AIDS patients is encouraging. Unfortunately the 
occurrence of relapse of infection is also re- 
ported. Optimization of liposome formulation as 
well as treatment regimens are needed to provide 
further therapeutic advantage of liposomal en- 
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